Associated Genetic Biomarkers
CHEK2 Nonsense is present in 0.13% of AACR GENIE cases, with bladder urothelial carcinoma, colon adenocarcinoma, lung adenocarcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence .
CHEK2 Nonsense serves as an inclusion eligibility criterion in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials that contain CHEK2 Nonsense as an inclusion criterion, 2 are phase 2 (2 open).
Trials with CHEK2 Nonsense in the inclusion eligibility criteria most commonly target breast carcinoma and prostate carcinoma .
Olaparib and durvalumab are the most frequent therapies in trials with CHEK2 Nonsense as an inclusion criteria .
Significance of CHEK2 Nonsense in Diseases
Breast Carcinoma +
CHEK2 is altered in 1.07% of breast carcinoma patients with CHEK2 Nonsense present in 0.1% of all breast carcinoma patients .
CHEK2 Nonsense is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK2 Nonsense and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
Prostate Carcinoma +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.